Core Viewpoint - The transaction between Fangsheng Pharmaceutical and Yifan Pharmaceutical involves the acquisition of the marketing authorization for "Compound Dexamethasone Acetate Cream," which is expected to enhance the company's product portfolio in dermatology and potentially serve as a new profit growth point [1] Group 1: Transaction Details - The contract was signed on September 30, 2025, and does not constitute a related party transaction or a major asset restructuring, falling within the chairman's approval authority [1] - The payment for the transaction will be made in three phases, indicating a structured financial approach to the acquisition [1] Group 2: Market Context - The drug is used for various skin diseases, with 103 companies in China holding production licenses for it [1] - In the first half of 2025, the sales revenue from physical pharmacies for this drug reached 175 million yuan, highlighting its market potential [1] Group 3: Strategic Implications - The acquisition aligns with the company's development strategy to expand its dermatological product offerings, which is expected to contribute positively to future revenue streams [1] - However, the timeline for completing the holder change procedures remains uncertain, and sales may be influenced by market factors, necessitating cautious decision-making by investors [1]